A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression

19Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Translocated in liposarcoma-CCAAT/enhancer binding protein homologous protein (TLS-CHOP) (also known as FUS-DDIT3) chimeric oncoprotein is found in the majority of human myxoid liposarcoma (MLS), but its molecular function remains unclear. Methods: We knockdowned TLS-CHOP expression in MLS-derived cell lines by a specific small interfering RNA, and analysed the gene expression profiles with microarray. Results: TLS-CHOP knockdown inhibited growth of MLS cells, and induced an anticancer cytokine, melanoma differentiation-associated gene 7 (MDA-7)/interleukin-24 (IL-24) expression. However, double knockdown of TLS-CHOP and MDA-7/IL-24 did not inhibit MLS cell growth. Conclusion: Repression of MDA-7/IL-24 expression by TLS-CHOP is required for MLS tumour growth, and TLS-CHOP may become a promising therapeutic target for MLS treatment. © 2012 Cancer Research UK All rights reserved.

Cite

CITATION STYLE

APA

Oikawa, K., Tanaka, M., Itoh, S., Takanashi, M., Ozaki, T., Muragaki, Y., & Kuroda, M. (2012). A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression. British Journal of Cancer, 106(12), 1976–1979. https://doi.org/10.1038/bjc.2012.199

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free